U.S. markets closed

CompuMed, Inc. (CMPD)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.36880.0000 (0.00%)
At close: 3:52PM EDT
Sign in to post a message.
  • b
    hey Fresno
    I also wrote to FTC a few years ago and they wrote me back which I never discussed with this board and there response surprised me they basically told me TO KEEP BUYING because they are also buying and expecting this to become a multi nation telehealth company ready to set new all time highs
  • H
    Im betting on more news shortly. I crunched the companies numbers and a fair stock price NOW is .70 cents. If you look 12 months ahead the stock value goes much higher! Im positive in one month from now we will be saying I WISH I BOUGHT MORE even at .40. Remember the insiders converted there stock to common stock this was the clear beginning.
  • T
    now we're beginning to see some serious competion for shares (emphasis on beginning)....breakinng historical highs Friday got the attention of many more investors....SP still grossly undervalued....not only does Healthcare believe that but I bet management does too.
  • T
    SP broke through historical resistance today to a new 52 week high. SP has demonstrated excellent resiliance since quarterly. Downside is volume was lowish so we'll see if this price sticks.
  • z
    Let’s count how long the next news or announcement will be! 1) it’s up due to the Q being release where everyone can see it! 2) in order for the next move to higher numbers it’ll need to release some news before the next Q release! 3) for it to get close to the ($) sign the next Q needs to surpass the last with better than expectation! 4) in order to find institution holders it’ll have to have new products or services to bring the price into the high $4s or low $5s without falling back to lower numbers.
    Let’s see how well the company perform before the next Q release!!
  • R
    Sorry Bagel,

    I'm Not Mr, 2,500
    Nor DP.
    Only ME
  • Q
    Come on compumed!!! Hit us with some great pr's.We know you have them,show us, the world what your made of.Come on Mr kiddie CEO WE KNOW YOUR A GENIUS,NOW SHOW THE WORLD!
  • b
    what we need is new blood in the game it cant be the same guys always buying because this gives the 2500 guy reason to still play at this level Once we go up north of 50 I truly believe he will be less and less influential in playing both sides But that is just my opinion
  • b
    Does anyone else get the feeling that Compumed is about to explode?

    I have this feeling and its nothing like the gut feelings i have had since 1999 something is different
  • Q
    So guys any guesses for the week?my guess....ANYTHING IS POSSIBLE...ANYTHING
  • T
    Read on the SD site:
    blog 1/19/19 "Digital Pathology Moving Organ Procurement to forefront of Kidney & Liver Biopsies"
    You'll see they may just be scratching the surface of telepathology's potential. You'll find links in text helpful.
    Upshot is new tech developments like digital scanners, WSI, and telepth. enabling pathology a much more vital role in diagnostics.
  • b
    Just sold my 3 bitcoin I bought yesterday for 50135 for 51666 for a nice 4500 profit in 28 hours
  • b
    Welcome back my friend
    And just to give a bitcoin update purchased more shares of Compuned on Thursday and was a nice amount with a small amount of profits from my bitcoin trading

    Actually if everyone of my Compumed friends that I communicate with are telling me the truth 5 of us own 4.5-5million shares between us and that is only 5 shareholders and this doesn’t include everyone on this board except 1
  • Q
    Anyone,is SD still doing business in California,from previous post that where deleted,it stated that for what ever reason they stopped doing business in California.Anyone what's the story
  • D
    Volume all but gone now.

    Hey Robert, explain that.

    I think it was you who said .40 for sure by weeks end (two weeks ago).

    Two yawns for you.
  • R
    CompuMed and its team of highly experienced physicians provide specialized diagnostic interpretations to their clients who need answers in high urgency situations. Organ Procurement Organizations (OPOs) which provide organs and tissue for transplant centers need critical information relating to for example pathology, cardiology, or radiology to improve donor management, decrease donor evaluation time prior to organ recovery, and to decrease the risk of organs being declined by transplant centers.

    Many of the specialized physician interpretations needed for organ management and evaluation are best done by those that have expertise in that specific area. In addition, these services are often needed in a fast turnaround time, often at night, over the weekends and holidays. Many of the donor hospitals are often not very large centers, and even in larger hospitals, key resources tend to be mainly allocated to treating living patients.

    “The OPO must often make do with late, and/or nontransplant-specific interpretations. Due to the large number of donor hospitals, over 50% of the donors come from a hospital that has less than two donors a year, this process involves a large number of pathologists, which by its very nature, results in inconsistencies,” explains Carie Kadric’, Vice President of Clinical Operations at CompuMed.

    Part of the evaluation process by pathologists for transplantation may include a biopsy performed at the time of procurement. The transplant center must view the biopsy by viewing the actual slide, therefore it must be physically transported, meaning that the initial hospital must provide a “provisional acceptance”: they will accept the organ and once they receive delivery of the organ and slide, they can make a final decision. This does not allow multiple transplant centers to view the slide in a timely manner and adds hours of time to an already procured organ, increasing the probability of it degrading.

    The ability to now digitize slides allows a smaller more specialized reading group of pathologists to perform slide interpretation creating more consistency by reducing the possibility of inter-observer bias. Digitized slides also allow multiple transplant centers to be able to view the slide remotely while reducing the trauma on the organ from multiple biopsies.

    CompuMed wanted to investigate the benefits of using AI for the pathology process of their services, focusing on two specific functions. Firstly, in improving the “screening” of the biopsy slide prior to it reaching the remote pathologist. There are a number of thresholds that are required to be met for a biopsy to be an acceptable representation of the organ. For example, a minimum number of Glomeruli are required to be visible in a kidney biopsy, and the evaluation of the quality of the digital slide and the viable biopsy area are also critical.

    “We felt that with the help of artificial intelligence we could greatly increase the confidence that what was being sent digitally to the pathologist would be acceptable and readable. This was especially important if the technician making the slide was on call as they may have already left by the time the pathologist indicated the slide or biopsy was unacceptable and they needed it to be redone,” describes Carie Kadric’.

    The second function was to assist the pathologist in their evaluation to help improve efficiency, accuracy, and consistency. A renal slide from a kidney biopsy may take 10 to 15 minutes to read manually. Much of the time is spent covering the complete slide to count Glomeruli and determining if any are sclerosed, or damaged. With the assistance of AI, CompuMed anticipates they will be able to increase the speed and accuracy of this evaluation.

    “We wanted to partner with a company that not only had a full AI platform that we could use ourselves, but we also wanted the flexibility of utilizing a platform that had a team that could do the AI development for us. In this way, we could utilize the AI team in the initial stages and any time we did not have the bandwidth,” explains Carie Kadric’. “ When we evaluated platforms, Aiforia came up at the top. But what really made the difference was the ease of working with their team. We feel the project has exceeded our expectations, not only with the resultant product, but also the value of the deliverable versus the cost.”

    CompuMed is currently using Aiforia’s cloud-based platform for kidney transplant pathology and looking to expand to other organs such as the liver. The kidney project is using deep learning AI through Aiforia to count Glomeruli and to indicate sclerotic ones, giving pathologists confidence in their decision making by providing them with fast, high-precision data ava
  • b
    RK Question

    you have also said that you have made money over the years on Compumed trading and I am beginning to understand how. There is a guy who I call the 2500 man who is constantly playing both sided of the trade. If this is you who has been doing this congratulations because if this is indeed you than you have the patience of a saint but over the last 10 years i went back you definitely made money buying and selling.
    but we all need the 2500 man(YOU MY FRIEND) to take a break and let this thing go north a bit. Seems like friday might of been a indicator that you have stopped for a bit
  • T
    Wasting the Gift of Life?
    Our discard rates for donated kidneys are at their highest ever, thanks in part to unreliable and inconsistent procurement biopsies that need to be re-examined. How can we do better?
    Sumit Mohan | 07/23/2019 | Longer Read

    At a Glance
    Many donor kidneys are discarded due to the findings of procurement biopsies
    These biopsies have issues with accuracy and consistency and are often read by pathologists with limited renal experience
    In our study, the findings of multiple procurement biopsies on the same kidney showed only a 64 percent agreement rate
    Standardization – and limiting our reliance on procurement biopsies – will lead to an increase in transplantation rates

    Once a potential kidney donor has been identified, a simple but crucial question arises. Should the organ be accepted for transplant – or turned away? Factors such as donor and recipient characteristics, anatomic and immunologic information, and longevity matching considerations all influence this call and must be considered quickly. To help inform the decision, surgeons carry out procurement biopsies while the organ is being obtained; these occur in around half of all deceased-donor kidneys in the US (1). Deceased donor kidneys are a scarce and valuable resource – but, alarmingly, we find ourselves facing the highest kidney discard rate of all time, with one in five donated organs going to waste (2, 3). The findings of procurement biopsies play a telling role in these rates; they are listed as the main reason for discard in around 37 percent of kidneys that are procured but ultimately not used (4).

    With the results of procurement biopsies contributing so heavily to the discard of potentially transplantable kidneys, it is vital to cast a critical eye over their efficacy at identifying organs that shouldn’t be transplanted. A number of analyses have already raised questions about the reproducibility and predictive value of procurement biopsies, so we conducted our own study to assess their reliability (4). Across 116 kidneys that had undergone multiple procurement biopsies, we found only a 64 percent agreement rate between different biopsies, suggesting low reliability and consistency when it comes to the information that they present. A similar agreement was found between procurement biopsies and gold-standard reperfusion biopsies performed after kidney implantation.

    The problem with procurement
    Why is there such poor agreement between procurement biopsies and reperfusion biopsies, as well as between sequential procurement biopsies? I think there are a number of factors that contribute to this inconsistency, starting with the environment in which they are conducted. There is great pressure to get these biopsies performed, processed, stained, and read in a relatively short space of time so that the surgeon can decide whether or not they want to keep the kidney. The biopsies tend to be frozen sections that are often read outside usual working hours (the “middle of the night phone call” is real!). Depending on who performs the biopsy and where it is completed, a hospital’s facilities can also have an impact. For example, smaller hospitals might not have a kidney biopsy needle and will therefore have to perform a wedge biopsy, which results in more subcapsular tissue and overestimation of scarring.

    There are a relatively small number of renal pathologists available compared with, for example, surgical pathologists.
    Other constraints with procurement biopsies arise because the frozen section procedure introduces a certain amount of artifact, making them difficult to interpret – an issue exacerbated by the fact that renal pathology is not a common skill. There are a relatively small number of renal pathologists available compared with, for example, surgical pathologists, so not everybody who reads the results of procurement biopsies has equal levels of experience. Additionally, given that they are often read in the middle of the night, it’s not infrequent for trainees with much less experience to take on the task, which naturally introduces the potential for error, even with supervision.

    Variability also occurs because there isn’t enough standardization in the reporting of results amongst surgeons who carry out procurement biopsies. This is, in part, the result of a small procurement biopsy paper published around 25 years ago that investigated glomerulosclerosis. It showed that kidneys with glomerulosclerosis coverage over 20 percent were not suitable for transplant, whereas those with less than 20 percent glomerulosclerosis performed well (5). Although not true across the board, this threshold for kidney quality has taken hold and is used by many centers to decline an organ.

    The issue is that there isn’t a standardized protocol to enforce this measure, so everyone uses their own version. Reports frequently vary from “less than/more than 20 percent glomerulosclerosis” to “mild/moderate/severe glomerulosclerosis.” It’